Skip to content
Kidney & Bladder — Beta-3 agonistsATC G04BD12

Mirabegron

Prescription only

Overactive bladder treatment without dry mouth.

Starts working
Varies
Half-life
About 50 hours
In use since
2012
Pregnancy
Usually avoided

Overview

Mirabegron relaxes the bladder by a different route from antimuscarinics, so it doesn't cause dry mouth, constipation or confusion. Blood pressure should be checked because it can raise it.

Conditions it's used for

How it works

Relaxes the bladder as it fills.

Mirabegron belongs to the Beta-3 agonists. How Beta-3 agonists work: relax the bladder muscle as it fills, so it holds more.

Uses

  • Overactive bladder

Available as: modified-release tablet, granules (children).

Typical dose

Adults
25–50 mg once a day.

Typical doses for orientation only. Your prescription, the pack leaflet and local guidance take priority.

Side effects

Common

Often mild and may settle with time

  • Raised heart rate
  • Urinary infections
  • Headache

Serious — get medical help

Uncommon, but need prompt attention

  • Severely raised blood pressure

Warnings

  • Not with severe uncontrolled high blood pressure

Interactions

  • Digoxin — levels rise
  • Metoprolol, other CYP2D6 substrates — levels rise
Check Mirabegron against your own medicines

Pregnancy and breastfeeding

Usually avoided

Not recommended.

Breastfeeding advice can differ from pregnancy advice — check with a pharmacist, or the LactMed database.

Brand names

United States
Myrbetriq
United Kingdom
Betmiga
India
Mirago, Mirabeg
Australia
Betmiga

Examples only; many generic versions exist. The same brand name can mean different products in different countries.

Common questions

Can it be combined with an antimuscarinic?

Yes, specialists sometimes combine them for stubborn symptoms.

Do I need a prescription for Mirabegron?

Yes — Mirabegron is prescription-only in most countries.

Can I take Mirabegron during pregnancy?

Usually avoided. Not recommended. Always check with a doctor or midwife.

Sources and official information

Entry last reviewed October 2026. Compiled from WHO, NHS, FDA/DailyMed, BNF and national formulary information. How we write entries.